Jeremy Adler, MD, MSc
Clinical Professor of Pediatrics
Interim Section Head, CHEAR
General Pediatrics

Available to mentor

Jeremy Adler, MD, MSc
Clinical Professor
  • About
  • Qualifications
  • Center Memberships
  • Recent Publications
  • About

    Jeremy Adler, M.D., M.Sc. is a Clinical Professor in the Division of Pediatric Gastroenterology at the University of Michigan and serves as the Interim Director of the Susan B. Meister Child Health Evaluation and Research (CHEAR) Center. Dr. Adler earned his M.D. degree at the University of South Florida College of Medicine. He completed his residency in pediatrics at Boston City Hospital and Boston Medical Center in 1997. He then practiced academic general pediatrics in New York for several years before moving to Michigan to train in pediatric gastroenterology at the University of Michigan. He then earned a Master of Science in Health and Health Care Research through in the Horace H. Rackham School of Graduate Studies at the University of Michigan, and had further training in the Advanced Improvement Methods program at Cincinnati Children’s Hospital. Dr. Adler joined the pediatric gastroenterology faculty at the University of Michigan in 2008.

    Dr. Adler's clinical and research interest is in the care of children and adolescents with Crohn's disease and ulcerative colitis (inflammatory bowel disease or IBD). His research focus is on improving short and long-term outcomes and health related quality of life for children with IBD. He has been working on developing evidence-based strategies for preventing disease related complications such as fistulas and pouchitis, and to mitigate disparities among children with IBD.

    Dr. Adler is an NIH-funded researcher whose scientific research has been featured in the American Gastroenterology Association's headline news, on the cover of the journal Inflammatory Bowel Diseases, and in the Innovations in Health Care section of the Wall Street Journal. Dr. Adler is a leader in the field of pediatric IBD, and has served as consultant to the US Food and Drug Administration, and his work on prevention of disease complications and on developing methods for evaluating endoscopic findings has been used in national and international policies and guidelines on treating children and adults with IBD. Dr. Adler also serves as the Director of Research and Quality Improvement in Pediatric Gastroenterology, and as the Director of the Pediatric IBD Program at C.S. Mott Children’s Hospital at Michigan Medicine.

    Qualifications
    • Adaptive Leadership
      University of Michigan, United states, 2024
    • Advanced Improvement Methods (AIM), Center for Health Care Quality
      Cincinnati Children's Hospital Medical Center, Cincinnati, 2015
    • Linkage Leadership Academy
      University of Michigan, Ann Arbor, 2015
    • Pediatric gastroenterology Fellowship
      C. S. Mott Children's Hospital, Ann Arbor, 2008
    • Pediatric Residency
      Boston Medical Center, Boston, 1997
    • MSc
      Horace H. Rackham School of Graduate Studies, University of Michigan, Ann Arbor, 2009
    • MD
      University of South Florida College of Medicine, 4202 E Fowler Ave, 1994
    • BS
      University of Florida, Gainesville, 1990
    Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Recent Publications See All Publications
    • Journal Article
      Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease.
      Brenner EJ, Weaver KN, Zhang X, Kastl AJ, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine A, Craig RG, Boccieri ME, Long MD, Kappelman MD. Clin Gastroenterol Hepatol, 2024 Jul; 22 (7): 1475 - 1486.e4. DOI:10.1016/j.cgh.2024.02.001
      PMID: 38369224
    • Journal Article
      High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
      Ebach DR, Jester TW, Galanko JA, Firestine AM, Ammoury R, Cabrera J, Bass J, Minar P, Olano K, Margolis P, Sandberg K, Linnville TM, Kaplan J, Pitch L, Steiner SJ, Bass D, Moses J, Adler J, Gulati AS, Wali P, Pashankar D, Ivanova A, Herfarth H, Wohl DA, Benkov KJ, Strople J, Sullivan J, Tung J, Molle-Rios Z, Saeed SA, Bousvaros A, Kappelman MD. Am J Gastroenterol, 2024 Jun 1; 119 (6): 1110 - 1116. DOI:10.14309/ajg.0000000000002741
      PMID: 38445644
    • Journal Article
      MRI and Blood-based Biomarkers Are Associated With Surgery in Children and Adults With Ileal Crohn's Disease.
      Dillman JR, Tkach JA, Fletcher JG, Bruining DH, Lu A, Kugathasan S, Alazraki AL, Knight-Scott J, Stidham RW, Adler J, Trapnell BC, Swanson SD, Fei L, Qian L, Towbin AJ, Kocaoglu M, Anton CG, Imbus RA, Dudley JA, Denson LA. Inflamm Bowel Dis, 2024 May 13; DOI:10.1093/ibd/izae101
      PMID: 38738296
    • Proceeding / Abstract / Poster
      Mo2039 COMPARISON OF ALL PEDIATRIC PATIENTS AND YOUNG ADULTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
      Saeed SA, Steiner S, Adler J, Colletti RB, Strauss R, Heile JM, Adedokun OJ, Sheahan A, Zhang R, Lo KH, Kim L, Xiao Y, Volger S. Gastroenterology, 2024 May; 166 (5): s - 1207. DOI:10.1016/s0016-5085(24)03231-1
    • Proceeding / Abstract / Poster
      Mo2040 COMPARISON OF PEDIATRIC PATIENTS AND YOUNG ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
      Steiner S, Saeed SA, Adler J, Colletti RB, Strauss R, Heile JM, Adedokun OJ, Sheahan A, Zhang R, Lo KH, Kim L, Xiao Y, Volger S. Gastroenterology, 2024 May; 166 (5): s - 1208. DOI:10.1016/s0016-5085(24)03232-3
    • Proceeding / Abstract / Poster
      Mo2049 THE EFFECT OF USTEKINUMAB ON MUCOSAL INFLAMMATION IN PEDIATRIC CROHN'S DISEASE: THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
      Adler J, Steiner SJ, Saeed S, Colletti RB, Strauss R, Godwin B, Sheahan A, Zhang R, Kim L, Xiao Y, Volger S. Gastroenterology, 2024 May; 166 (5): s - 1212. DOI:10.1016/s0016-5085(24)03241-4
    • Journal Article
      Tu1843 LONG-TERM EFFECTIVENESS AND DURABILITY OF SARS-COV-2 VACCINATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
      Brenner EJ, Weaver K, Zhang X, Kastl A, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PD, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine AM, Craig R, Boccieri M, Long MD, Kappelman M. Gastroenterology, 2024 May; 166 (5): s-1432-s-1433 DOI:10.1016/s0016-5085(24)03744-2
    • Proceeding / Abstract / Poster
      Tu1844 MAGNITUDE OF SARS-COV-2 SPIKE ANTIBODY LEVEL FOLLOWING VACCINATION IS NOT ASSOCIATED WITH RISK OF DEVELOPING SYMPTOMATIC COVID-19 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
      Brenner EJ, Weaver K, Zhang X, Kastl A, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PD, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine AM, Craig R, Boccieri M, Long MD, Kappelman M. Gastroenterology, 2024 May; 166 (5): s - 1433. DOI:10.1016/s0016-5085(24)03745-4